<DOC>
	<DOCNO>NCT00372489</DOCNO>
	<brief_summary>The purpose study evaluate long term safety tolerability peginesatide maintenance hemoglobin participant chronic kidney disease ( CKD ) receive least 24 week peginesatide treatment earlier study .</brief_summary>
	<brief_title>Extension Study Evaluate Safety Tolerability Peginesatide Long-Term Treatment Anemia Participants With CKD</brief_title>
	<detailed_description>Anemia associate chronic kidney disease due several factor , primarily inability diseased kidney produce adequate amount endogenous erythropoietin . Ancillary factor include shorten lifespan red blood cell , iron nutritional deficiency , infection , inflammation . The presence severity anemia related duration extent kidney failure . Anemia associate increased mortality , increase likelihood hospitalization , reduce cognitive function , increase leave ventricular hypertrophy heart failure . Erythropoiesis stimulate agent establish treatment anemia subject chronic kidney disease , improved management anemia alternative transfusion . Peginesatide parenteral formulation develop treatment anemia associate chronic kidney disease . Peginesatide bind activate human erythropoietin receptor , stimulate erythropoiesis human red cell precursor manner similar know erythropoiesis-stimulating agent ( ESAs ) . Study participant receive least 24 week peginesatide dose previous Affymax-sponsored study ( NCT00228449 ) receive dos peginesatide approximately 54 month . However , Sponsor end study early .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Participant inform investigational nature study give write , witness informed consent accordance institutional , local , national guideline Males female ≥ 18 year age . Premenopausal female ( exception surgically sterile ) must negative pregnancy test screening ; sexually active must practice highly effective method birth control least 4 week prior study drug administration , must willing continue contraception least 4 week last dose study drug . Participant receive least 24 week peginesatide dose previous Affymaxsponsored study One hemoglobin value &gt; 10.0 g/dL 4 week prior study drug administration Known intolerance peginesatide pegylated product History antibody erythropoiesis stimulate agent ( ESA ) history pure red cell aplasia ( PRCA ) High likelihood early withdrawal interruption study ( e.g. , participant suffers clinically significant medical disease condition may , Investigator 's opinion , interfere safety , assessment , followup participant ) Anticipated life expectancy &lt; 18 month Receipt ESA peginesatide time participant enrollment previous Affymaxsponsored study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>CRF</keyword>
	<keyword>dialysis</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>Hematide™</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>Omontys</keyword>
	<keyword>peginesatide</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>